Oncolytics Biotech Cash And Equivalents vs. Book Value Per Share
| ONC Stock | CAD 1.20 0.02 1.64% |
Cash And Equivalents | First Reported 2010-12-31 | Previous Quarter 13.4 M | Current Value 14.1 M | Quarterly Volatility 4.8 M |
For Oncolytics Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncolytics Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncolytics Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncolytics Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncolytics Biotech over time as well as its relative position and ranking within its peers.
Oncolytics |
Oncolytics Biotech Book Value Per Share vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncolytics Biotech's current stock value. Our valuation model uses many indicators to compare Oncolytics Biotech value to that of its competitors to determine the firm's financial worth. Oncolytics Biotech is considered to be number one stock in cash and equivalents category among its peers. It also is considered to be number one stock in book value per share category among its peers . The ratio of Cash And Equivalents to Book Value Per Share for Oncolytics Biotech is about 31,529,730 . At this time, Oncolytics Biotech's Cash And Equivalents is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Oncolytics Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oncolytics Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Oncolytics Book Value Per Share vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Oncolytics Biotech |
| = | 11.67 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Oncolytics Biotech |
| = | 0.37 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Oncolytics Book Value Per Share Comparison
Oncolytics Biotech is currently under evaluation in book value per share category among its peers.
Oncolytics Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncolytics Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncolytics Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Oncolytics Biotech's change in net profit over the period of time. It can combine multiple indicators of Oncolytics Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 544 K | 516.8 K | |
| Operating Income | -33.8 M | -32.1 M | |
| Net Loss | -27.8 M | -29.1 M | |
| Income Tax Expense | 97 K | 92.2 K | |
| Income Before Tax | -27.7 M | -29 M | |
| Total Other Income Expense Net | 6.1 M | 6.4 M | |
| Net Loss | -27.8 M | -29.1 M | |
| Net Loss | -22.4 M | -23.5 M | |
| Interest Income | 1.3 M | 1.8 M | |
| Net Interest Income | 1.3 M | 1.4 M | |
| Change To Netincome | 801.5 K | 761.5 K | |
| Net Loss | (0.41) | (0.43) | |
| Income Quality | 1.03 | 0.71 | |
| Net Income Per E B T | 1.00 | 0.81 |
Oncolytics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncolytics Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncolytics Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncolytics Biotech's important profitability drivers and their relationship over time.
Use Oncolytics Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.Oncolytics Biotech Pair Trading
Oncolytics Biotech Pair Trading Analysis
The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oncolytics Biotech position
In addition to having Oncolytics Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Fabricated Products Thematic Idea Now
Fabricated Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Fabricated Products theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Fabricated Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
To fully project Oncolytics Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Oncolytics Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Oncolytics Biotech's income statement, its balance sheet, and the statement of cash flows.